Ischemic Stroke Clinical Trial
Official title:
Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST): a Prospective, Random, Double Blinded and Multi-center Study
Verified date | August 2023 |
Source | General Hospital of Shenyang Military Region |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke.
Status | Recruiting |
Enrollment | 1022 |
Est. completion date | July 28, 2024 |
Est. primary completion date | July 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old; - Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset; - NIHSS = 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination; - Premorbid mRS = 1; - Signed informed consent. Exclusion Criteria: - Premorbid mRS=2; - Uncontrolled severe hypertension (systolic pressure >180 mmHg or diastolic pressure >110 mmHg after drug treatment); - Antithrombotic treatment within 24 hours before randomization; - Significant dysphagia and inability to take the experimental drug orally; - Allergy or contraindication to study drugs; - Comorbidity with any serious diseases and life expectancy is less than half a year; - Participating in other clinical trials within three months; - Patients not suitable for this clinical study considered by researcher |
Country | Name | City | State |
---|---|---|---|
China | Department of Neurology, General Hospital of Northern Theater Command | Shenyang | |
China | Hui-sheng Chen | ShenYang | None Selected |
Lead Sponsor | Collaborator |
---|---|
General Hospital of Shenyang Military Region |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of excellent prognosis | excellent prognosis is defined as modified Rankin Score (mRS) 0-1. The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome | Day 90 | |
Secondary | The proportion of favorable prognosis | Favorable prognosis is defined as modified Rankin Score (mRS) 0-2. The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome. | Day 90 | |
Secondary | Distribution of modified Rankin Score (mRS) | The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome. | Day 90 | |
Secondary | Changes in National Institute of Health stroke scale (NIHSS) | the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome. | 24 hours, 48 hours, and 10 days | |
Secondary | Occurrence of early neurologyical deterioration (END) | END is defined as more than 2 point increase, but not result of cerebral hemorrhage, compared with baseline at 24 hours | 24 hours | |
Secondary | The incidence of symptomatic intracerebral hemorrhage | any evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score =4 points increase) | 36 hours | |
Secondary | The incidence of any intracerebral hemorrhage | the evidence of bleeding on the head CT or MRI scan | 36 hours | |
Secondary | The incidence of stroke recurrence and other vascular events | Day 90 | ||
Secondary | The death due to any cause | Day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02924168 -
Radial Shock Waves for Functional Disability in Stroke
|
N/A |